US2022023286A1PendingUtilityA1

Pharmaceutical composition for treatment of aortic aneurysm

60
Assignee: NATIONAL UNIV CORPORATION HAMAMATSU UNIV SCHOOL OF MEDICINEPriority: Sep 13, 2017Filed: Oct 12, 2021Published: Jan 27, 2022
Est. expirySep 13, 2037(~11.1 yrs left)· nominal 20-yr term from priority
Inventors:Naoki UnnoHiroki TanakaTatsuro YataKeisuke InoueYuichi MakinoseNoboru Kaneta
A61K 31/4704A61K 31/704A61P 9/14A61P 9/10
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention addresses the problem of providing a therapeutic agent for abdominal aortic aneurysms, with which pharmacotherapy is possible. The present invention provides a therapeutic agent for an aortic aneurysm comprising, as an active component, (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these.

Claims

exact text as granted — not AI-modified
1 - 7 . (canceled) 
     
     
         8 . A method for treating an aortic aneurysm, comprising:
 administering an effective amount of (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt, or a solvate, or a solvate of the salt thereof to a subject in need of treatment,   wherein the subject is a patient with aortic aneurysm selected from the group consisting of abdominal aortic aneurysms, thoracoabdominal aortic aneurysms, and thoracic aortic aneurysms.   
     
     
         9 . The method according to  claim 8 , wherein the treatment of the aortic aneurysm includes at least one treatment selected from the group consisting of suppression of aneurysm rupture, suppression of aneurysm dilatation, and aneurysm size reduction. 
     
     
         10 . The method according to  claim 9 , wherein the treatment of the aortic aneurysm is suppression of aortic aneurysm rupture. 
     
     
         11 . The method according to  claim 9 , wherein the treatment of the aortic aneurysm is suppression of aortic aneurysm rupture after endovascular stent-grafting. 
     
     
         12 . The method according to  claim 9 , wherein the treatment of the aortic aneurysm is suppression of aortic aneurysm rupture before endovascular stent-grafting or aortic aneurysmectomy. 
     
     
         13 . The method according to  claim 9 , wherein the treatment of the aortic aneurysm is suppression of aortic aneurysm dilatation. 
     
     
         14 . The method according to  claim 9 , wherein the treatment of the aortic aneurysm is suppression of aortic aneurysm dilatation after endovascular stent-grafting. 
     
     
         15 . The method according to  claim 9 , wherein the treatment of the aortic aneurysm is suppression of aortic aneurysm dilatation before endovascular stent-grafting or aortic aneurysmectomy. 
     
     
         16 . The method according to  claim 9 , wherein the treatment of the aortic aneurysm is aortic aneurysm size reduction. 
     
     
         17 . The method according to  claim 8 , wherein the subject is a patient with abdominal aortic aneurysm. 
     
     
         18 . The method according to  claim 9 , wherein the subject is a patient with abdominal aortic aneurysm. 
     
     
         19 . A method for suppressing aortic aneurysm rupture, comprising:
 administering an effective amount of (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt, or a solvate, or a solvate of the salt thereof to a subject in need of treatment,   wherein the subject is a patient with aortic aneurysm selected from the group consisting of abdominal aortic aneurysms, thoracoabdominal aortic aneurysms, and thoracic aortic aneurysms.   
     
     
         20 . The method according to  claim 19 , wherein the aortic aneurysm rupture is an aortic aneurysm rupture after endovascular stent-grafting. 
     
     
         21 . The method according to  claim 19 , wherein the aortic aneurysm rupture is an aortic aneurysm rupture before endovascular stent-grafting or aortic aneurysmectomy. 
     
     
         22 . The method according to  claim 19 , wherein the subject is a patient with abdominal aortic aneurysm. 
     
     
         23 . A method for suppressing aortic aneurysm dilatation, comprising:
 administering an effective amount of (−)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt, or a solvate, or a solvate of the salt thereof to a subject in need of treatment,   wherein the subject is a patient with aortic aneurysm selected from the group consisting of abdominal aortic aneurysms, thoracoabdominal aortic aneurysms, and thoracic aortic aneurysms.   
     
     
         24 . The method according to  claim 23 , wherein the aortic aneurysm dilatation is an aortic aneurysm dilatation after endovascular stent-grafting. 
     
     
         25 . The method according to  claim 23 , wherein the aortic aneurysm dilatation is an aortic aneurysm dilatation before endovascular stent-grafting or aortic aneurysmectomy. 
     
     
         26 . The method according to  claim 23 , wherein the subject is a patient with abdominal aortic aneurysm.

Join the waitlist — get patent alerts

Track US2022023286A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.